A prospective observational open-label study to evaluate the effect of telmisartan on glycosylated hemoglobin and fasting plasma glucose levels in hypertensive patients with impaired fasting glycaemia

2022 ◽  
Vol 12 (7) ◽  
pp. 1
Author(s):  
Veena H ◽  
Narendranath S ◽  
Vinay Yeli
Keyword(s):  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Glycosylated Hemoglobin ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Hypertensive Patients ◽  
Impaired Fasting Glycaemia ◽  
Glucose Levels ◽  
Fasting Glycaemia

scholarly journals Effect of telmisartan in hypertensive patients with impaired fasting glycaemia

2017 ◽  
Vol 6 (6) ◽  
pp. 1261
Author(s):  
Bheemesh Naidu Mattam ◽  
Zaheda Bano ◽  
Meenakumari A. ◽  
V. L. M. Raman
Keyword(s):  
Blood Pressure ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Ppar Gamma ◽  
Nuclear Hormone Receptor ◽  
Angiotensin Ii Receptor Blocker ◽  
Hypertensive Patients ◽  
Impaired Fasting Glycaemia ◽  
Fasting Plasma ◽  
Fasting Glycaemia

Background: Telmisartan, an angiotensin II receptor blocker, has a higher affinity for AT1 receptors. It has also been recognized as partial agonist of the nuclear hormone receptor PPAR-gamma. The present study is conducted to study the effect of Telmisartan in hypertensive patients with impaired fasting glycaemia.Methods: This is a prospective and randomised study done on 50 hypertensive patients with impaired fasting glycaemia. All the patients underwent following investigations like Fasting plasma glucose, blood pressure and body mass index were also measured.Results: Fasting plasma glucose, blood pressure (SBP, DBP) showed significant decrease after intake of 40 mg Telmisartan for three months. Changes in BMI are not significant.Conclusions: The present study shows that Telmisartan is effective in controlling blood-pressure by its AT1 receptor blocking activity. It is also effective in decreasing fasting blood glucose by its insulin sensitizing activity through partial peroxisome proliferator activated receptor (PPAR) gamma activity.

scholarly journals MP121THE EFFECT OF CILNIDIPINE ON INTRADIALYTIC BLOOD PRESSURE IN INTRADIALYTIC HYPERTENSIVE PATIENTS: A MULTICENTER, PROSPECTIVE, RANDOMIZED, OPEN-LABEL STUDY

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii472-iii472 ◽  
Author(s):  
Takayasu Ito ◽  
Naoki Fujimoto ◽  
Eiji Ishikawa ◽  
Kaoru Dohi ◽  
Michiyo Kiyohara ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Hypertensive Patients

Evaluation of long-term efficacy and tolerability of irbesartan in elderly hypertensive patients with renal impairment in an open-label study

2002 ◽  
Vol 63 (3) ◽  
pp. 201-215 ◽  
Author(s):  
Maria Leonarda De Rosa ◽  
Piercarmine Cardace ◽  
Massimiliano Rossi ◽  
Antonio Baiano ◽  
Alessandro de Cristofaro
Keyword(s):  
Renal Impairment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Hypertensive Patients ◽  
Term Efficacy ◽  
Elderly Hypertensive ◽  
Elderly Hypertensive Patients

Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. The QoLaN study

2009 ◽  
Vol 18 ◽  
pp. 5-14
Author(s):  
Michel Hermans ◽  
Olivier De Coster ◽  
Laurence Seidel ◽  
Adelin Albert ◽  
Philippe Van De Borne
Keyword(s):  
Quality Of Life ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Hypertensive Patients

Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. The QoLaN study

2009 ◽  
Vol 18 (sup1) ◽  
pp. 5-14 ◽  
Author(s):  
Michel P. Hermans ◽  
Olivier De Coster ◽  
Laurence Seidel ◽  
Adelin Albert ◽  
Philippe Van De Borne
Keyword(s):  
Quality Of Life ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Hypertensive Patients
Sign in / Sign up

Export Citation Format

Share Document